Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Moodys
McKesson
Express Scripts
McKinsey

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR CANDESARTAN CILEXETIL


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Candesartan Cilexetil

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00108706 ↗ Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST) Unknown status Takeda Phase 4 2004-12-01 The aim of this study is to determine whether it is safe and effective to give the Angiotensin Receptor Blocker (ARB) Candesartan within the first 72 hours following acute stroke.
NCT00108706 ↗ Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST) Unknown status City Hospitals Sunderland NHS Foundation Trust Phase 4 2004-12-01 The aim of this study is to determine whether it is safe and effective to give the Angiotensin Receptor Blocker (ARB) Candesartan within the first 72 hours following acute stroke.
NCT00120003 ↗ Scandinavian Candesartan Acute Stroke Trial (SCAST) Completed AstraZeneca Phase 3 2005-06-01 The purpose of this trial is to assess whether the blood pressure lowering agent candesartan (an angiotensin receptor type 1 blocker) is effective when given to patients with acute stroke and elevated blood pressure. Hypothesis: AT1 receptor blockade with candesartan in acute stroke will: 1. reduce the risk of death or major disability at 6 months by a 6% absolute risk reduction, relative to placebo. 2. reduce the risk of the combined event of "vascular" death, myocardial infarction, or stroke during the first 6 months by a 25% relative risk reduction, relative to placebo
NCT00120003 ↗ Scandinavian Candesartan Acute Stroke Trial (SCAST) Completed Southern-Eastern Norway Health Authorities RHF Phase 3 2005-06-01 The purpose of this trial is to assess whether the blood pressure lowering agent candesartan (an angiotensin receptor type 1 blocker) is effective when given to patients with acute stroke and elevated blood pressure. Hypothesis: AT1 receptor blockade with candesartan in acute stroke will: 1. reduce the risk of death or major disability at 6 months by a 6% absolute risk reduction, relative to placebo. 2. reduce the risk of the combined event of "vascular" death, myocardial infarction, or stroke during the first 6 months by a 25% relative risk reduction, relative to placebo
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Candesartan Cilexetil

Condition Name

Condition Name for Candesartan Cilexetil
Intervention Trials
Hypertension 30
Essential Hypertension 5
Healthy 4
Stroke 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Candesartan Cilexetil
Intervention Trials
Hypertension 40
Essential Hypertension 10
Heart Failure 4
Stroke 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Candesartan Cilexetil

Trials by Country

Trials by Country for Candesartan Cilexetil
Location Trials
United States 101
Japan 32
Korea, Republic of 22
China 17
Germany 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Candesartan Cilexetil
Location Trials
California 6
Florida 5
Texas 5
Ohio 5
North Carolina 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Candesartan Cilexetil

Clinical Trial Phase

Clinical Trial Phase for Candesartan Cilexetil
Clinical Trial Phase Trials
Phase 4 12
Phase 3 26
Phase 2/Phase 3 1
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Candesartan Cilexetil
Clinical Trial Phase Trials
Completed 47
Unknown status 12
Withdrawn 4
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Candesartan Cilexetil

Sponsor Name

Sponsor Name for Candesartan Cilexetil
Sponsor Trials
AstraZeneca 23
Takeda 14
CJ HealthCare Corporation 7
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Candesartan Cilexetil
Sponsor Trials
Industry 71
Other 42
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
AstraZeneca
Moodys
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.